Association Between Cardiac Conduction Defect and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis

Overview

Journal Ann Gastroenterol

Specialty Gastroenterology

Date 2020 Nov 9

PMID 33162743

Citations 5

Authors

Karn Wijarnpreecha

Panadeekarn Panjawatanan

Paul T Kroner

Wisit Cheungpasitporn

Patompong Ungprasert

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease is a common comorbidity of patients with nonalcoholic fatty liver disease (NAFLD), particularly coronary artery disease and congestive heart failure. However, the relation between NAFLD and cardiac conduction defects has not been well studied. This systematic review and meta-analysis was conducted to identify all available studies on this association and summarize their results.

Methods: A comprehensive literature review was conducted using MEDLINE and EMBASE databases through June 2020 to identify studies that compared the risk of a cardiac conduction defect among patients with NAFLD versus those without. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.

Results: Three cross-sectional studies with 3651 participants fulfilled the eligibility criteria and were included in this meta-analysis. The risk of a cardiac conduction defect was significantly higher among patients with NAFLD than in those without NAFLD, with a pooled odds ratio of 5.17 (95% confidence interval 1.34-20.01; 96%).

Conclusion: A significantly greater risk of cardiac conduction defects among patients with NAFLD was observed in this meta-analysis. How this risk should be managed in clinical practice requires further investigation.

Citing Articles

Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist.

Millan-Rodriguez C, Castello C, Caballero-Valderrama M, Esquivias G Eur Cardiol. 2024; 18:e64.

PMID: 38213666 PMC: 10782421. DOI: 10.15420/ecr.2023.22.

How non-alcoholic fatty liver disease and cirrhosis affect the heart.

Moller S, Wiese S, Barlose M, Hove J Hepatol Int. 2023; 17(6):1333-1349.

PMID: 37770804 DOI: 10.1007/s12072-023-10590-1.

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications.

Boccatonda A, Andreetto L, DArdes D, Cocco G, Rossi I, Vicari S Biomedicines. 2023; 11(3).

PMID: 36979861 PMC: 10046146. DOI: 10.3390/biomedicines11030883.

Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses.

Zhong L, Wu C, Li Y, Zeng Q, Lai L, Chen S Ther Adv Chronic Dis. 2022; 13:20406223221083508.

PMID: 35620184 PMC: 9127863. DOI: 10.1177/20406223221083508.

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.

Gutierrez-Cuevas J, Santos A, Armendariz-Borunda J Int J Mol Sci. 2021; 22(21).

PMID: 34769060 PMC: 8583943. DOI: 10.3390/ijms222111629.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Gaggini M, Morelli M, Buzzigoli E, DeFronzo R, Bugianesi E, Gastaldelli A . Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5(5):1544-60. PMC: 3708335. DOI: 10.3390/nu5051544. View

Dowman J, Tomlinson J, Newsome P . Pathogenesis of non-alcoholic fatty liver disease. QJM. 2009; 103(2):71-83. PMC: 2810391. DOI: 10.1093/qjmed/hcp158. View

Chung M, Martin D, Sprecher D, Wazni O, Kanderian A, Carnes C . C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104(24):2886-91. DOI: 10.1161/hc4901.101760. View

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Chung G, Lee J, Lee H, Kim M, Yim J, Choi S . Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis. 2018; 272:137-144. DOI: 10.1016/j.atherosclerosis.2018.03.027. View

Lee S, Park G, Lee J, Lee B, Park J, Kim B . Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. J Hepatol. 2017; 68(5):1018-1024. DOI: 10.1016/j.jhep.2017.12.012. View

Herzog R, Alvarez-Pasquin M, Diaz C, Del Barrio J, Estrada J, Gil A . Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health. 2013; 13:154. PMC: 3602084. DOI: 10.1186/1471-2458-13-154. View

10.

Targher G, Day C, Bonora E . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363(14):1341-50. DOI: 10.1056/NEJMra0912063. View

11.

LaBrecque D, Abbas Z, Anania F, Ferenci P, Khan A, Goh K . World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014; 48(6):467-73. DOI: 10.1097/MCG.0000000000000116. View

12.

Salvarani N, Maguy A, De Simone S, Miragoli M, Jousset F, Rohr S . TGF-β (Transforming Growth Factor-β) Plays a Pivotal Role in Cardiac Myofibroblast Arrhythmogenicity. Circ Arrhythm Electrophysiol. 2017; 10(5):e004567. DOI: 10.1161/CIRCEP.116.004567. View

13.

Mantovani A, Rigolon R, Pichiri I, Bonapace S, Morani G, Zoppini G . Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS One. 2017; 12(10):e0185459. PMC: 5628831. DOI: 10.1371/journal.pone.0185459. View

14.

Whalley S, Puvanachandra P, Desai A, Kennedy H . Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med (Lond). 2007; 7(2):119-24. PMC: 4951824. DOI: 10.7861/clinmedicine.7-2-119. View

15.

Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

16.

Wijarnpreecha K, Boonpheng B, Thongprayoon C, Jaruvongvanich V, Ungprasert P . The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis. Clin Res Hepatol Gastroenterol. 2017; 41(5):525-532. DOI: 10.1016/j.clinre.2017.08.001. View

17.

Wijarnpreecha K, Thongprayoon C, Edmonds P, Cheungpasitporn W . Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: a systematic review and meta-analysis. QJM. 2015; 109(7):461-466. DOI: 10.1093/qjmed/hcv172. View

18.

Mangi M, Minhas A, Rehman H, Pathan F, Liang H, Beidas S . Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram. Cureus. 2017; 9(3):e1107. PMC: 5400518. DOI: 10.7759/cureus.1107. View

19.

De Coster T, Claus P, Kazbanov I, Haemers P, Willems R, Sipido K . Arrhythmogenicity of fibro-fatty infiltrations. Sci Rep. 2018; 8(1):2050. PMC: 5795000. DOI: 10.1038/s41598-018-20450-w. View

20.

Wainwright P, Byrne C . Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci. 2016; 17(3):367. PMC: 4813227. DOI: 10.3390/ijms17030367. View